Cisplatin, mitomycin, and interferon-alpha 2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma
CHEST, vol.116, no.2, pp.391-398, 1999 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 116 Issue: 2
- Publication Date: 1999
- Doi Number: 10.1378/chest.116.2.391
- Journal Name: CHEST
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.391-398
- Eskisehir Osmangazi University Affiliated: Yes
Abstract
Study objective: To investigate the therapeutic activity and toxicity of combination chemoimmunotherapy with cisplatin, mitomycin, and interferon (IFN)-alpha 2a, by comparing the responses in a group of patients with diffuse malignant pleural mesothelioma (DMPM) to the responses in a control group of DMPM patients given supportive care alone.